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Abstract: BACKGROUND Systematic work-up of patients with myocardial infarction and non-obstructive
coronary artery disease (MINOCA) using cardiac magnetic resonance imaging (CMR) led to a more than
six-fold increase in the detection rate of myocarditis. In this study, we expanded on our prior two-year
analysis by including preceding and subsequent years. METHODS We performed a retrospective chart
review of patients with angina-like symptoms and elevated high-sensitivity troponin T (TnT-hs ge;14
ng/l) but without significant coronary artery disease, from 2011 to 2017. Patients underwent CMR to
test for myocarditis. From 2011 to 2015, only patients with elevated TnT-hs, no significant coronary
artery disease and moderate to high clinical likelihood of suffering from myocarditis, underwent CMR.
In 2016 and 2017, CMR images were obtained from all patients with MINOCA, independent of the clin-
ical likelihood that patients were suffering from myocarditis. RESULTS A total of 556 patients who
underwent CMR (70.5% male, 57 plusmn; 17 years, with an average left ventricular ejection fraction
of 51 plusmn; 15%) qualified for inclusion in this studyrsquo;s analysis. From 2011 to 2015, 240 CMR
examinations were performed, with the number increasing to 316 between 2016 and 2017. In total, my-
ocarditis was diagnosed in 76 out of the 556 patients (13.7%). Between 2011 and 2015, the detection
rate of myocarditis was 12.7 per 100,000 hospitalisations and increased 4.9-fold (p lt;0.0001), to 62.5 per
100,000 hospitalisations, between 2016 and 2017. CONCLUSION A novel diagnostic algorithm led to
an average 4.9-fold increase in the rate of myocarditis detection in our hospital over the two subsequent
years. This highlights that myocarditis continues to be underdiagnosed when CMR is not systematically
used in patients with MINOCA. nbsp.
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Summary
BACKGROUND: Systematic work-up of patients with my-
ocardial infarction and non-obstructive coronary artery dis-
ease (MINOCA) using cardiac magnetic resonance imag-
ing (CMR) led to a more than six-fold increase in the
detection rate of myocarditis. In this study, we expanded
on our prior two-year analysis by including preceding and
subsequent years.
METHODS: We performed a retrospective chart review
of patients with angina-like symptoms and elevated high-
sensitivity troponin T (TnT-hs ≥14 ng/l) but without sig-
nificant coronary artery disease, from 2011 to 2017. Pa-
tients underwent CMR to test for myocarditis. From 2011
to 2015, only patients with elevated TnT-hs, no significant
coronary artery disease and moderate to high clinical like-
lihood of suffering from myocarditis, underwent CMR. In
2016 and 2017, CMR images were obtained from all pa-
tients with MINOCA, independent of the clinical likelihood
that patients were suffering from myocarditis.
RESULTS: A total of 556 patients who underwent CMR
(70.5% male, 57 ± 17 years, with an average left ventric-
ular ejection fraction of 51 ± 15%) qualified for inclusion
in this study’s analysis. From 2011 to 2015, 240 CMR ex-
aminations were performed, with the number increasing to
316 between 2016 and 2017. In total, myocarditis was di-
agnosed in 76 out of the 556 patients (13.7%). Between
2011 and 2015, the detection rate of myocarditis was
12.7 per 100,000 hospitalisations and increased 4.9-fold
(p <0.0001), to 62.5 per 100,000 hospitalisations, between
2016 and 2017.
CONCLUSION: A novel diagnostic algorithm led to an
average 4.9-fold increase in the rate of myocarditis de-
tection in our hospital over the two subsequent years.
This highlights that myocarditis continues to be underdiag-
nosed when CMR is not systematically used in patients
with MINOCA.
Keywords: cardiac magnetic resonance imaging, my-
ocarditis, CMR-based work-up
Introduction
Myocarditis is a heterogeneous inflammatory heart disease
which manifests itself through a variety of symptoms [1,
2]. Over time, its clinical development can take an adverse
trajectory and result in dilated cardiomyopathy (DCM),
impaired left ventricular ejection fraction (LVEF) [3], ma-
lignant arrhythmias and sudden cardiac death (SCD) [2,
4–6]. Even though endomyocardial biopsy and cardiac
magnetic resonance imaging (CMR) are increasingly used
to diagnose myocarditis [2, 7, 8], the true incidence of
myocarditis remains unknown [9]. Post mortem studies
have identified myocarditis in up to 42% [5, 10] of cases
of SCD, suggesting a significant epidemiological impact.
Hence, a systematic change of the diagnostic algorithm
may be necessary to improve the rate of myocarditis detec-
tion in patients [11].
As symptoms of myocarditis can mimic myocardial infarc-
tion and lead to elevated troponin levels [2] [12], inflam-
matory cardiomyopathy is commonly found amongst pa-
tients with angina-like symptoms, elevated high-sensitivity
troponin-T (TnT-hs) and unobstructed coronaries (i.e. my-
ocardial infarction and non-obstructive coronary artery dis-
ease [MINOCA]) [13–15]. This clinically challenging pop-
ulation often does not receive specific treatment [16, 17]
and was found to display an increased mortality rate [18].
In patients with MINOCA, multiple underlying mecha-
nisms have been suspected to be the cause of the disease,
including coronary spasm, coronary microvascular dys-
function, myocarditis, Takotsubo syndrome (TTS), sponta-
neous coronary thrombosis and emboli [18]. Interestingly,
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myocarditis is one of the most common underlying causes
within this patient population, with the percentage of cases
ranging from 16 to 50% [19, 20].
While endomyocardial biopsy (EMB) remains the gold
standard [21] for the diagnosis of myocarditis, CMR has
been established as a non-invasive alternative for the diag-
nosis of myocarditis, when EMB is not indicated [14, 22].
In a previous pilot study, we showed that the introduction
of a novel diagnostic algorithm using a lowered threshold
for CMR led to a 6.3-fold increase of the incidence of my-
ocarditis in patients with MINOCA. Furthermore, the al-
gorithm increased the percentage of CMRs that tested pos-
itive for myocarditis [23]. In order to confirm these first
results, we expanded our analysis to the preceding and sub-
sequent years, thereby evaluating a potential temporary in-
cidence peak in 2016. We hypothesised that the detection
rate of myocarditis would continue to be higher in 2017,
when CMR was systematically applied, compared to the
detection rate between 2011 and 2015, when CMR was
performed only when there had been moderate to high clin-
ical suspicion of myocarditis.
Methods
Study design
This was a retrospective single-centre study investigating a
new diagnostic algorithm for myocarditis amongst patients
with MINOCA. The study was performed at the Univer-
sity Hospital of Zurich, a tertiary health care centre with
980 hospital beds, covering the catchment area of the Can-
ton of Zurich with approximately 1.5 million citizens. The
cohort includes patients who were admitted to the Univer-
sity Hospital Zurich between January 2011 and December
2017 with angina-like symptoms, elevated levels of TnT-hs
(reference range 0–14 ng/l) and non-obstructive coronary
artery disease (CAD) (<50% stenosis) and who underwent
CMR for further diagnostic work-up. CAD was excluded
using coronary angiography by cardiac catheterization or
computed tomography (CT) and CMR if pretest probabil-
ity of CAD was very low [23]. No patients were exclud-
ed. CMR analyses were performed under the supervision
of the head of cardiac imaging who performed CMR be-
tween early 2011 and late 2018 and who had more than
eleven years of experience in CMR.
In the years 2011 to 2015, only patients with classical
symptoms of myocarditis, such as chest pain, dyspnoea
and palpitations after viral prodrome, underwent CMR.
Starting in 2016, the threshold for CMR imaging was low-
ered to examine all unexplained cases of MINOCA in line
with current guidelines [24]. A MRI was performed within
90 days after symptom onset.
Outcome measurements
The primary goal of this study was to measure the detec-
tion rate of myocarditis amongst patients suffering from
MINOCA, using systematic CMR work-up at our institu-
tion, the University Hospital Zurich, before and after im-
plementation of a new diagnostic work-up algorithm. To
evaluate the impact of this use of CMR, we compared the
number of detected cases of myocarditis after its introduc-
tion in 2016 and 2017 with the preceding five years, from
2011 to 2015.
In addition, we compared baseline characteristics of pa-
tients with MINOCA without signs for myocarditis, with
the characteristics of patients suffering from myocarditis.
We described the presence of other types of cardiomy-
opathies identified by CMR amongst patients with
MINOCA at the University Hospital Zurich between 2011
and 2017. Finally, we evaluated potential differences in our
baseline characteristics between patients with myocarditis
and MINOCA in order to evaluate potential clinical differ-
ences.
Clinical database
Clinical data were generated with the help of the Univer-
sity Hospital Zurich’s electronic medical records database.
All patients were anonymised and numbered sequential-
ly. IBM SPSS Statistics version 22 and MedCalc version
18.5 were used to carry out calculations and analysis. The
study was approved by the Ethics Committee of Zurich
(PB_2016_01152).
CMR examination
CMR images were generated using a 1.5 or 3.0 Tesla scan-
ner (SiemensSkyra, Erlangen, Germany or Phillips Achie-
va Best, Netherlands) with electrocardiography-gated
breath-hold protocol and weight-adapted dose of gadolin-
ium-based contrast agent (Gadovist, Bayer AG, Zurich,
Switzerland) (0.1 mmol/kg). Diagnosis of myocarditis was
based on cine-CMR, T2-weighted imaging and Late
Gadolinium Enhancement (LGE) images [25–27]. Edema
was assessed using T2-weighted images. Images were ob-
tained using a surface coil [25–27]. LGE images were
acquired 10 minutes after an intravenous injection of a
gadolinium-based contrast agent and were used to detect
necrosis. LGE was categorised according to its localisa-
tion, distribution and pattern using the 17 segment model.
Epicardial or midwall distribution of LGE, associated with
a patchy pattern and non-coronary distribution, were re-
garded as potential indicators for myocarditis.
Statistical analysis
Descriptive statistics were used to examine clinical data.
Metric scale parameters were described as averages ac-
companied by their standard deviation. Nominal scale pa-
rameters were reported as total numbers and as percentages
of the total number of patients who underwent CMR in a
particular year. Diagnoses of rare diseases, such as sclero-
derma, pericardial effusion and coronary anomalies, were
summarised as “others”. Baseline characteristics of pa-
tients with myocarditis vs. normal CMR findings were
compared using Student’s t-test and chi-square test for
equality of proportions. A p-value <0.05 was considered
significant for all statistical tests.
In order to compare the detection rate for myocarditis by
CMR in 2016 and 2017 with that between 2011 and 2015,
percentages of positive CMR findings for myocarditis for
each time interval were compared using the chi-square test.
Detection rate among the total number of patients who un-
derwent CMR at the University Hospital of Zurich was
calculated. The detection ratio compares the total rate be-
tween 2011 and 2015 to that between 2016 and 2017.
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Results
Baseline characteristics
A total of 556 patients who were admitted to hospital with
MINOCA between January 2011 and December 2017, un-
derwent CMR. The mean age of this group was 57 years
(range 19–92 years) with 392 (70.5%) male patients and an
average LVEF of 51 ± 15% measured by CMR (table 1).
The median time between symptom onset and CMR was
10 days (IQR 4–23 days).
Patterns of myocarditis were present in 76 patients
(13.7%), DCM in 34 (6.1%), ischaemia during stress in 41
(7.4%), hypertrophic (HCM) in 15 (2.7%), pericarditis in
13 (2.3%), amyloidosis in 8 (1.4%), TTS in 7 (1.3%), sar-
coidosis in 5 (0.9%), Fabry’s disease in 3 (0.5%) and “oth-
er” diagnoses were present in 22 patients (4%). In total,
332 (59.7%) of the performed CMRs were deemed unre-
markable (table 2).
Comparison of detection rates in 2011–2015 with
2016–2017
There was no difference in the length of time between
symptom onset and CMR between the two time periods (11
[IQR 5–24] vs 10 [IQR 3–23]). Of the total 556 patients
initially idenfied as suffering from MINOCA, 35 (6.3%)
cases occured in 2011, 27 (4.9%) in 2012, 28 (5%) in 2013,
62 (11.2%) in 2014, 88 (15.8%) in 2015, 199 (35.8%) in
2016 and 117 (21%) in 2017. This means that 240 (43.2%)
patients enrolled during the time period from 2011 to 2015,
while 316 (56.8%) did so during the years 2016 and 2017.
There was no difference in baseline parameters such as
age, gender or LVEF between these two time periods. The
average number of CMRs performed annually was 48 from
2011 to 2015. This number increased to 158 during the
years 2016 to 2017. There were significantly fewer annual
cases of DCM (p = 0.0072) from 2015 to 2016, while the
average annual proportion of CMR reports that tested neg-
ativeF for any pathology did not change (p = 0.25; table 3).
In total, 24 cases of myocarditis were identified between
2011 and 2015 vs. 52 cases between 2016 and 2017, result-
Table 1: Baseline parameters of patients undergoing cardiac magnetic resonance imaging in the years 2011–2017.
Year 2011 2012 2013 2014 2015 2016 2017 Total
Number of patients n = 35 n = 27 n = 28 n = 62 n = 88 n = 199 n = 117 n = 556
Male, n (%) 26 (74.3) 18 (66.7) 22 (78.6) 36 (58.1) 71 (80.7) 139 (70) 80 (68.4) 392 (71)
Age, % ± δ 54 ± 16 56 ± 17 55 ± 15 52 ± 17 66 ± 15 60 ± 16 49 ± 18 57 ± 17
LVEF, % ± δ 45 ± 19 52 ± 18 56 ± 15 52 ± 15 48 ± 15 51 ± 13 54 ± 14 51 ± 15
LVEF = left ventricular ejection fraction
Table 2: Diagnoses based on cardiac magnetic resonance imaging in the years 2011–2017.
Year 2011 2012 2013 2014 2015 2016 2017 Total
CMRs performed n = 35 n = 27 n = 28 n = 62 n = 88 n = 199 n = 117 n = 556
Normal heart, n (%) 18 (51.4) 13 (48.1) 14 (50) 43 (69.4) 68 (77.3) 110 (55) 66 (56.4) 332 (60)
Myocarditis, n (%) 6 (17.1) 4 (14.8) 5 (17.8) 5 (8.1) 4 (4.5) 26 (13.1) 26 (22.2) 76 (13.7)
Ischaemia, n (%) 1 (2.9) 1 (3.7) 1 (3.6) 1 (1.6) 8 (9.1) 26 (13.1) 3 (2.6) 41 (7.4)
Pericarditis, n (%) 0 (0) 0 (0) 1 (3.6) 2 (3.2) 0 (0) 4 (2) 6 (5.1) 13 (2.3)
Amyloidosis, n (%) 1 (2.9) 0 (0) 0 (0) 1 (1.6) 1 (1.1) 2 (1) 3 (2.6) 8 (1.4)
Sarcoidosis, n (%) 1 (2.9) 0 (0) 0 (0) 0 (0) 1 (1.1) 1 (0.5) 2 (1.7) 5 (0.9)
FD, n (%) 0 (0) 1 (3.7) 0 (0) 0 (0) 1 (1.1) 1 (0.5) 0 (0) 3 (0.5)
TTS, n (%) 0 (0) 0 (0) 1 (3.6) 0 (0) 0 (0) 4 (2) 2 (1.7) 7 (1.3)
DCM, n (%) 6 (17.1) 6 (22.3) 6 (21.4) 9 (14.5) 0 (0) 1 (0.5) 6 (5.1) 34 (6.1)
HCM, n (%) 2 (5.7) 2 (7.4) 0 (0) 0 (0) 2 (2.3) 9 (4.5) 0 (0) 15 (2.7)
Others, n (%) 0 (0) 0 (0) 0 (0) 1 (1.6) 3 (3.4) 15 (7.5) 3 (2.6) 22 (4)
FD = Fabry`s disease; TTS = takotsubo syndrome; DCM = dilated cardiomyopathy; HCM = hypertrophic cardiomyopathy
Table 3: Diagnoses based on cardiac magnetic resonance imaging in in the years 2011–2015 vs 2016–2017.
Year 2011–2015 2016–2017 p-value for χ2 equality of propor-




Days to CMR, median (IQR) 11 (5-24) 10 (3-23) 0.26
Normal heart, µ (%) 31.2 (65) 88 (55.7) 0.25
Myocarditis, µ (%) 4.8 (10) 26 (16.4) 0.28
Ischaemia, µ (%) 2.4 (5) 14.5 (9.2) 0.35
Pericarditis, µ (%) 0.6 (1.3) 5 (3.2) 0.48
Amyloidosis, µ (%) 0.6 (1.3) 2.5 (1.6) 0.88
Sarcoidosis, µ (%) 0.4 (0.8) 1.5 (0.9) 0.95
FD, µ (%) 0.4 (0.8) 0.5 (0.3) 0.64
TTS, µ (%) 0.2 (0.4) 3 (1.9) 0.46
DCM, µ (%) 5.4 (11.2) 3.5 (2.2) 0.0072
HCM, µ (%) 1.2 (2.5) 4.5 (2.9) 0.97
Others, µ (%) 0.8 (1.7) 9 (5.7) 0.26
CMR = cardiac magnetic resonance imaging; FD = Fabry`s disease; TTS = takotsubo syndrome; DCM = dilated cardiomyopathy; HCM = hypertrophic cardiomyopathy
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ing in 4.8 (10%) cases of myocarditis on average between
2011 and 2015 and 26 (16.7%) cases on average between
2016 and 2017.
In total, 272,688 patients were hospitalised at the Uni-
versity Hospital of Zurich from 2011 to 2017 (37,520 in
2011, 36,484 in 2012, 36,941 in 2013, 38,896 in 2014,
39,694 in 2015, 41,121 in 2016, 42,032 in 2017). As a re-
sult, the annual detection rate was 12.7 per 100,000 (CI
0.00008–0.00019) hospitalisations in the years 2011 to
2015. This number increased to 62.5 per 100,000 hospital-
isations (CI 0.00047–0.00083) in the period of time from
2016 to 2017, resulting in an detection ratio of 4.9 (p
<0.0001). The detection rate for each year is shown in fig-
ure 1.
Myocarditis vs MINOCA
We identified 76 cases of myocarditis between 2011 and
2017. Patients suffering from myocarditis were significant-
ly younger (47 ± 17 years vs 58 ± 17; p = 0.00000075)
and more likely to be male (81.6 vs 68.8%; p = 0.023) than
MINOCA patients, in whom no CMR signs of myocarditis
could be detected. Average LVEF on CMR was 51 ± 14%
and did not differ between the two groups.
Discussion
During the course of this study, we found a remarkable in-
crease in the detection rate of myocarditis at the Univer-
sity Hospital Zurich over two subsequent years as a result
of the implementation of a systematic CMR work-up algo-
rithm for patients suffering from MINOCA.
We recently reported the detection rate of myocarditis in
2015 vs 2016 at the University Hospital Zurich following
the implementation of a novel diagnostic work-up algo-
rithm in January 2016 in a pilot study, in which patients
with MINOCA were given a systematic work-up through
CMR [23]. We were able to detect a 6.3-fold increase in
the approximated incidence of myocarditis. Following the
success of this algorithm, it was decided to continue with it
in 2017. Through this new, additional study we were able
to verify our earlier results over a longer time period. We
compared the number of cases of myocarditis diagnosed by
CMR in patients suffering from MINOCA in 2016–2017,
with the number of identified cases of myocarditis in the
previous years, 2011–2015, in which the threshold for per-
forming CMR in patients with MINOCA was higher. The
finding of a 4.9-fold increase in the total detection rate of
myocarditis between 2016 and 2017 based on CMR and
clinical findings compared to previous years, suggests that
Figure 1: Detection rate of myocarditis diagnosed using cardiac
magnetic resonance imaging in the years2011–2017.
myocarditis continues to be underdetected. This supports
the notion that diagnostic work-up tools have to be im-
proved [1, 5, 14, 15, 20, 23, 28, 29]. Nonetheless, the ex-
act incidence of myocarditis cannot be fully determined,
as a definitive diagnosis would require myocardial biop-
sy, which has limitations itself. A previous study by Kar-
jalainen, Heikkilä and colleagues which evaluated the inci-
dence of myocarditis in young military recruits in Finland
from 1977 until 1996, based on clinical criteria, found my-
ocarditis to occur in 17 per 100,000 person years [1].
While the detection rate of myocarditis increased between
2016 and 2017, the annual percentage of CMR testing pos-
itive for myocarditis did not change significantly over the
years. This was despite patients without typical symptoms
of myocarditis having been included in 2016 and 2017.
This finding suggests that the diagnosis can be challeng-
ing if based on medical history and physical examination
only. Pathik and colleagues demonstrated that a clinical-
ly suspected diagnosis by cardiologists in patients with
MINOCA was changed in approximately 50% of cases af-
ter applying the CMR technique, demonstrating that clini-
cal identification of the etiology of MINOCA is challeng-
ing [30].
Similarly to previous studies, we found myocarditis to be
the most common underlying cause in patients who suffer
from MINOCA and who undergo CMR [14, 15, 18, 23].
Interestingly, the percentage of CMR scans which tested
positive for myocarditis (22.2% in 2017) was lower than
previously described in literature. For instance, Pasupathy
et al. found myocarditis to be present in 33% of CMRs in
MINOCA patients based on 26 publications [18]. More-
over, studies on the diagnostic yield of CMR in MINOCA
showed myocarditis to be present in 41.6–59.9% [14, 15].
In addition, they revealed a considerably lower rate of un-
remarkable CMR scans with only 8–10.3% [14, 15] com-
pared to the rates we found in our study (in total, 59.7%).
However, we did include all CMR scans with a clinical
suspicion of myocarditis, while the afore-mentioned stud-
ies excluded patients suffering from known cardiac dis-
eases. This could have led to higher concentrations of rele-
vant findings in the other publications.
Consistent with previous studies, patients with myocarditis
were significantly younger and more frequently male than
those who were not diagnosed with myocarditis [14, 31].
LVEF did not vary between cases of myocarditis and non-
myocarditis with a globally just mildly impaired LVEF (51
± 15%). Other underlying cause diagnoses in CMR, with
the exception of DCM, did not differ between the periods
of time 2011–2015 and 2016–2017.
In summary, systematic work-up of patients with
MINOCA implemented in 2016 led to an almost five-fold
increase in the diagnosis of myocarditis for two consecu-
tive years compared to the preceding five years. While the
lack of tissue diagnosis is a limitation of this study, wide
diagnostic work-up with low risk of complications can on-
ly be applied through a non-invasive approach. Thus, this
non-invasive approach provides an approximation of the
true incidence of myocarditis.
Due to the retrospective character of the study, as well
as the single centre design, the global applicability of our
results is limited. As mentioned above, a limitation of
this study was that histopathological confirmation of my-
Original article Swiss Med Wkly. 2019;149:w20098
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 4 of 6
ocarditis was not performed because we followed the
guidelines for endomyocardial biopsy, which restrict the
indication for endomyocardial biopsy as a more severe
clinical course [25]. Moreover, CMR diagnosis was per-
formed within three months of, rather than immediately
upon, symptom onset. This may have affected CMR find-
ings, since edema and LGE are dynamic and, in general,
regress during the clinical course. Furthermore, we did not
use the most recent T1 and T2 mapping techniques, which
could have led to a higher detection rate of myocarditis on
CMR [32].
Conclusion
The successful identification of the underlying illness of
patients with MINOCA may be challenging without addi-
tional diagnostic imaging. We have demonstrated that sys-
tematic work-up of patients with angina-like symptoms, el-
evated troponin and no significant coronary artery disease,
lea to an almost five-fold increase in the diagnosis of my-
ocarditis in our tertiary care centre. These data suggest that
myocarditis remains underdiagnosed and that lowering the
threshold for diagnostic work-up with CMR may help to
identify myocarditis early. Timely and accurate diagnosis
is crutial as certain subtypes of myocarditis require specif-
ic therapy. Furthermore, following diagnosis of myocardi-
tis, strenuous activity should be avoided for three to six
weeks, since the risk of exercise-induced arrhythmias may
be higher during that period.
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